Hematologic Malignancy
T-Cell and NK-Cell Neoplasm
CI-CAN-00001561Explore in graph →
HematologicNon-malignant268 active trials13 approved drugs18 evidence items
- NCIt
- C27908
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001561Explore in graph →
Clinical trials
1,103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02856997 | Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma | unknown | Phase 2 | 35 | Yuankai ShiOTHER | 0 | Aug 5, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01871675 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | completed | Phase 1 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01556828 | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | terminated | — | 70 | Stanford UniversityOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT02017613 | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies(PI3K) | completed | Phase 1 | 35 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Jun 24, 2016 | clinicaltrials |
| NCT01991158 | GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT01274533 | Lenalidomide in HTLV-1 Adult T-Cell Leukemia | completed | Phase 2 | 4 | Columbia UniversityOTHER | 1 | May 23, 2016 | clinicaltrials |
| NCT00898404 | Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate | completed | — | 150 | Children's Oncology GroupNETWORK | 1 | May 11, 2016 | clinicaltrials |
| NCT01950364 | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma | completed | Phase 1 | 20 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | May 11, 2016 | clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02080234 | Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02539472 | Early Diagnosis of Mycosis Fungoides(DIAPREMYF) | unknown | N/A | 620 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00322985 | A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT02296398 | Long-term Use of Romidepsin in Patients With CTCL | completed | — | 47 | Northwestern UniversityOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT01466881 | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 2 | Mar 10, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00178841 | Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | completed | Phase 2 | 4 | Vanderbilt UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 0 | Feb 3, 2016 | clinicaltrials |
| NCT01748721 | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Jan 8, 2016 | clinicaltrials |
| NCT01788137 | A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients | unknown | Phase 3 | 380 | Sun Yat-sen UniversityOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT01430013 | Trial of Endostar Combined With CHOPT for T Cell Lymphoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00131937 | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2015 | clinicaltrials |
| NCT01435863 | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) | completed | Phase 1 | 17 | Solasia Pharma K.K.INDUSTRY | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01959477 | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant | completed | Early Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT02520219 | Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study | unknown | Phase 2 | 60 | Nanjing NingQi Medicine Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 11, 2015 | clinicaltrials |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas(PXD101-CLN-6) | terminated | Phase 2 | 53 | Valerio TherapeuticsINDUSTRY | 5 | Jul 28, 2015 | clinicaltrials |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01501136 | Treatment of Natural Killer/T Cell Lymphoma-I/II(CTTNKTL-I/II) | unknown | Phase 4 | 200 | Mingzhi ZhangOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT01501149 | Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ(CTTNKTL-Ⅲ/Ⅳ) | unknown | Phase 4 | 80 | Mingzhi ZhangOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT01403415 | Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2015 | clinicaltrials |
| NCT00431912 | A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma | completed | Phase 2 | 25 | Valerio TherapeuticsINDUSTRY | 4 | Jul 8, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00720135 | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | withdrawn | Phase 2 | 0 | Stefan Schieke MDOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00453427 | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas(ACCAPELA) | completed | Phase 1 / Phase 2 | 20 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT00003210 | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00099593 | Immunization Against Tumor Cells in Sezary Syndrome | completed | Phase 2 | 17 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00254332 | Effect of Denileukin Diftitox on Immune System in CTCL Patients | completed | — | 10 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01198665 | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas(RADCHOP) | completed | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT01238159 | Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma | completed | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT00337987 | A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma | completed | Phase 2 | 49 | Yale UniversityOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00079755 | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma | completed | Phase 2 | 80 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT02229682 | Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Sep 30, 2014 | clinicaltrials |
| NCT01689220 | A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea | completed | Phase 1 | 6 | Solasia Pharma K.K.INDUSTRY | 1 | Sep 4, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2016source: clinicaltrials